• CLS is an industry partner in a five-year, $2.98 million NIH-funded research program led by Dartmouth Health.
• The program advances MRI-guided laser therapy for spinal metastases from laboratory and preclinical validation toward clinical evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CLS - Clinical Laserthermia Systems AB published the original content used to generate this news brief via Cision (Ref. ID: 20261029:BIT:1717:0) on October 29, 2026, and is solely responsible for the information contained therein.